Search

Your search keyword '"Bonadona, V."' showing total 232 results

Search Constraints

Start Over You searched for: Author "Bonadona, V." Remove constraint Author: "Bonadona, V."
232 results on '"Bonadona, V."'

Search Results

3. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

4. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

5. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

6. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

7. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

9. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

10. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

11. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

12. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

13. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

14. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers.

15. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

16. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

17. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

20. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

21. The contribution of germline rearrangements to the spectrum of BRCA2 mutations

22. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

23. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

24. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

25. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

26. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

27. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

29. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

30. Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study.

31. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

32. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

33. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

34. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

36. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

37. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

38. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma†

39. Location of mutation in BRCA2 gene and survival in patients with ovarian cancer

40. Classification des familles de type sein–ovaire sans mutation constitutionnelle de BRCA1/2 identifiée, pour le niveau de risque de cancer du sein : apport d’une stratégie d’évaluation multicritères s’appuyant sur une méthode d’analyse factorielle

41. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

42. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

43. 1003P - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

44. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

45. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

46. Short-Term Risk of Colorectal Cancer in Individuals With Lynch Syndrome: A Meta-Analysis

47. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

49. Tamoxifen and risk of contralateral breast cancer for \textitBRCA1 and \textitBRCA2 mutation carriers

50. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

Catalog

Books, media, physical & digital resources